| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 1,023,000 | 1,301,000 | 1,074,000 | 1,024,000 | 982,000 |
| Sales Growth | -21.37% | +21.14% | +4.88% | +4.28% | -6.92% |
| Net Income | -129,000 | 23,000 | -101,000 | -206,000 | -759,000 |
| Net Income Growth | -660.87% | +122.77% | +50.97% | +72.86% | -590.00% |
Catalent Inc
(CTLT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs (protein, cell, and gene therapy biologics) and consumer health products.
Fiscal Year End Date: 06/30